^
    Back
    Association details:
    Biomarker:VEGFA +405GG genotype
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Genet Test Mol Biomarkers
    Title:

    Investigation of Vascular Endothelial Growth Factor Polymorphisms on Risk, Metastasis, Laterality, and Prognosis of Colorectal Cancer in Turkish Subjects

    Published date:
    05/20/2022
    Excerpt:
    A total of 153 subjects consisting of 74 controls and 79 CRC diagnosed patients were included in the study. Patients with VEGF +405GG genotype showed longer progression-free survival as a response to bevacizumab treatment (Log rank = 6.92, p = 0.03).
    DOI:
    10.1089/gtmb.2021.0213